NASDAQ: RXDXPrometheus Biosciences Inc Stock
$198.80-0.03 (-0.02%)
Updated Jun 5, 2023
RXDX Price
$198.80
Fair Value Price
N/A
Market Cap
$9.50B
52 Week Low
$22.31
52 Week High
$198.99
P/E
-56.48x
P/B
13.62x
P/S
1,274.98x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.00M
Earnings
-$150.56M
Gross Margin
100%
Operating Margin
-3,768.76%
Profit Margin
-3,768.8%
Debt to Equity
0.09
Operating Cash Flow
-$133M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
RXDX Overview
Prometheus Biosciences Incorporated develops and commercializes novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases. Its lead product is PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trials for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. Prometheus Biosciences was incorporated in 2016 and is headquartered in San Diego, CA.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RXDX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RXDX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RXDX is poor value based on its book value relative to its share price (13.62x), compared to the US Biotechnology industry average (5.21x)
P/B vs Industry Valuation
RXDX is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RXDX due diligence checks available for Premium users.
Be the first to know about important RXDX news, forecast changes, insider trades & much more!
RXDX News
Valuation
RXDX fair value
Fair Value of RXDX stock based on Discounted Cash Flow (DCF)
Price
$198.80
Fair Value
$200.65
Undervalued by
0.92%
RXDX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RXDX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-56.48x
Industry
11.59x
Market
53.21x
RXDX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
13.62x
Industry
5.21x
RXDX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RXDX's financial health
Profit margin
Revenue
$1.1M
Net Income
-$40.9M
Profit Margin
-3,699.2%
RXDX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
RXDX's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$758.4M
Liabilities
$60.8M
Debt to equity
0.09
RXDX's short-term assets ($726.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RXDX's short-term assets ($726.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RXDX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$39.5M
Investing
-$192.3M
Financing
$52.8M
RXDX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RXDX vs Biotech Stocks
Prometheus Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.